Attached files
file | filename |
---|---|
8-K - FORM 8-K - HeartWare International, Inc. | c23781e8vk.htm |
Exhibit
99.1
HEARTWARE INTERNATIONAL ANNOUNCES PLANNED DEPARTURE OF
CHIEF FINANCIAL OFFICER
CHIEF FINANCIAL OFFICER
Third Quarter Conference call tomorrow at 8:00 a.m. U.S. E.T.
Framingham, Mass. and Sydney, Australia, October 27, 2011 HeartWare International, Inc. (NASDAQ:
HTWR; ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support
technologies that are revolutionizing the treatment of advanced heart failure, announced today that
David McIntyre, Chief Financial Officer and Chief Operating Officer, plans to relocate with his
family back to Australia for personal reasons and will be leaving the
Company. Mr. McIntyre will continue
with his responsibilities for the remainder of this year and will be available throughout 2012 to
assist with Australian operations and investor relations as needed.
David has played a key role in the growth of HeartWare, and his leadership has helped successfully
position the Company for expanded global commercialization of our devices, stated Doug Godshall,
President and Chief Executive Officer. We respect his desire to return to Australia, and move
away from a public-company environment in order to focus more attention on family. We are grateful
for his many contributions, and wish David and his family well in the
future.
For more than five years, Lauren Farrell, Vice President of Finance, has played an essential role
in the management of the finance function and, more broadly, in ensuring the integrity of our
financial analysis and reporting, added Mr. Godshall. With a deep understanding of our business,
Lauren will be an integral part of our transition and we look forward to her continued outstanding
stewardship of our financial reporting.
Third Quarter Results and Conference Call with HeartWare Management
Separately
today, HeartWare is announcing financial results for the third quarter ended September 30,
2011, including revenues of $21.3 million, a 54 percent increase from $13.8 million in revenues for
the same period of 2010. HeartWare will host a conference call on Friday, October 28, 2011 at 8:00
a.m. U.S. Eastern Daylight Time (11:00 p.m. Australian Eastern Daylight Time, Friday, October 28,
2011) to discuss the Companys financial results, highlights from the quarter and business outlook.
The call may be accessed by dialing 1-877-941-2068 five minutes prior to the scheduled start time
and referencing HeartWare. For callers outside the U.S., please dial +1-480-629-9712.
- more -
A live
webcast of the call will also be available at the Companys
website (www.heartware.com) by
selecting HeartWare Third Quarter 2011 Conference Call under the section titled Corporate
Presentations on the Home Page. A replay of the conference call will be available through the
above weblink immediately following completion of the call.
About HeartWare International
HeartWare International develops and manufactures miniaturized implantable heart pumps, or
ventricular assist devices, to treat Class IIIB / IV patients suffering from advanced heart
failure. The HeartWare® Ventricular Assist
System features the HVAD® pump, a small full-output circulatory support device (up to
10L/min flow) designed to be implanted next to the heart, avoiding the abdominal surgery generally
required to implant competing devices. HeartWare has received CE Marking for the HeartWare System
in the European Union and TGA approval in Australia. The device is currently the subject of United
States clinical trials for two indications: bridge-to-transplant and destination therapy. For
additional information, please visit www.heartware.com.
HeartWare International, Inc. is a member of the Russell 2000® and its securities are
publicly traded on The NASDAQ Stock Market and the Australian Securities Exchange.
HEARTWARE, HVAD, MVAD and HeartWare logos are registered trademarks of HeartWare, Inc.
Forward-Looking Statements
This announcement contains forward-looking statements that are based on managements beliefs,
assumptions and expectations and on information currently available to management. All statements
that address operating performance, events or developments that we expect or anticipate will occur
in the future are forward-looking statements, including without limitation our expectations with
respect to the timing and progress of, and presentation of data related to, clinical trials,
expected timing of regulatory filings and approvals, research and development activities and
changes in executive management. Management believes that these forward-looking statements are
reasonable as and when made. However, you should not place undue reliance on forward-looking
statements because they speak only as of the date when made. HeartWare does not assume any
obligation to publicly update or revise any forward-looking statements, whether as a result of new
information, future events or otherwise. HeartWare may not actually achieve the plans, projections
or expectations disclosed in forward-looking statements, and actual results, developments or events
could differ materially from those disclosed in the forward-looking statements. Forward-looking
statements are subject to a number of risks and uncertainties, including without limitation, the
possibility the FDA does not accept our PMA application or approve the marketing of the
HeartWare® Ventricular Assist System in the U.S., and those described in Item 1A. Risk
Factors in our Annual Report on Form 10-K filed with the Securities and Exchange Commission. We
may update our risk factors from time to time in Part II, Item 1A Risk Factors in our Quarterly
Reports on Form 10-Q, Current Reports on Form 8-K, or other filings with the Securities and
Exchange Commission.
For further information:
Christopher Taylor
HeartWare International, Inc.
Email: ctaylor@heartwareinc.com
Phone: +1 508 739 0864
Christopher Taylor
HeartWare International, Inc.
Email: ctaylor@heartwareinc.com
Phone: +1 508 739 0864
2